1. Why a 2026 Nootropics API Price List
The "nootropics" category inside a wholesale research-chemical catalog is structurally different from peptides or prostaglandins: most catalog racetams have been off-patent for decades, so the supply side is dominated by generic-API manufacturers in India and China rather than by Western CDMOs. Piracetam (CAS 7491-74-9, originally UCB 1964) has been produced at multi-ton scale for ~40 years; the per-kilogram price in 2026 for 99 % HPLC-verified material is in the USD 8-12 / kg range at 1-ton lots, compared with USD 600-700 / kg for a structurally related but lower-volume racetam like pramiracetam (CAS 68497-62-1). The spread between "everyday" racetams and "specialty" nootropics is therefore about two orders of magnitude, driven by synthesis-route complexity and annual volume, not by pharmacological novelty.
Three structural facts shape the 2026 price list:
- Off-patent generics vs specialty racetams. Piracetam, aniracetam, oxiracetam, and Noopept (omberacetam, CAS 157115-85-0) are off-patent small molecules with several approved API sites globally. Pramiracetam, fasoracetam, NSI-189, and tropoflavin are specialty molecules with 1-3 API sites each; pricing tracks R&D amortization, not commodity supply.
- Eugeroic wake-promoter analog cluster. Modafinil (CAS 68693-11-8) and its analogs adrafinil (CAS 63547-13-7), armodafinil (CAS 112111-43-0), flmodafinil / CRL-40,940 (CAS 90280-13-0), and fladrafinil / hydrafinil / CRL-40,941 (CAS 1689-64-1) form a tight structural cluster where a quotation issued against one is not interchangeable with another.
- Flavone derivatives vs racetams. Tropoflavin (4′-DMA-7,8-dihydroxyflavone, CAS 38183-03-8) and 7,8-dihydroxyflavone (CAS 38183-03-8) are flavone-class TrkB partial agonists, not racetams — their synthesis routes are flavone-specific (Baker-Venkataraman / Algar-Flynn-Oyamada) and the CDMO supplier pool overlaps less with racetam CDMOs.
2. The Wholesale Tier Framework (T1 → T4)
The same four-tier framework that structures the peptide price list applies here. Differences from peptide tiers: the T3 commercial-GMP band is narrower for off-patent racetams (smaller premium over T2) because Chinese API sites already operate at cGMP for these molecules; the T4 brand-GMP premium does not exist for any of these 9 SKUs in 2026.
| Tier | Indicative purity | Microbial / endotoxin | Documentation pack | Typical use |
|---|---|---|---|---|
| T1 Research | ≥ 98 % HPLC | Not tested | CoA only | In vitro pharmacology, screening libraries |
| T2 Preclinical | ≥ 99 % HPLC | Total plate count, USP <61> | CoA + 1H-NMR + LC-MS | Animal PK/PD, formulation screening |
| T3 Commercial cGMP | ≥ 99.5 % HPLC, chiral purity where applicable | USP <61> + <62> + bacterial endotoxin (where applicable) | DMF / ASMF / CEP available, ICH Q3C residual solvents, ICH Q3D elemental impurities | Generic-drug formulation, EU/US import, ANDA / generic dossier |
| T4 Brand innovator | ≥ 99.8 %, full genotoxic-impurity panel | Full panel incl. mycoplasma | Full NDA-grade CMC dossier | Innovator launch — none of the 9 SKUs here reach T4 in 2026 |
3. Catalog at a Glance — 9 Wholesale SKUs
Wholesale tier benchmarks consolidated across three independent CDMO quotations and three trading-company quotations, normalised to USD per kilogram at T2 (≥99 % HPLC) for the standard 1 kg pack size. Prices for smaller pack sizes (1 g, 10 g, 100 g) and larger pack sizes (10 kg, 25 kg) follow the same scaling rules described in §4 and §5.
| API | CAS | Class | 2026 T2 benchmark (USD / kg) | Pack-size range |
|---|---|---|---|---|
| Piracetam | 7491-74-9 | Prototype racetam (UCB, 1964) | USD 8 – 12 / kg | 1 g · 100 g · 1 kg · 25 kg |
| Noopept (omberacetam) | 157115-85-0 | Cyclic dipeptide racetam mimetic | USD 245 – 265 / kg | 1 g · 10 g · 100 g · 1 kg · 5 kg |
| Phenibut (free acid) | 1078-21-3 | GABA-B agonist, β-phenyl-GABA | USD 125 – 145 / kg | 1 kg · 5 kg · 25 kg |
| Aniracetam | 72432-10-1 | AMPA-positive allosteric racetam | USD 145 – 165 / kg | 1 kg · 5 kg · 25 kg |
| Oxiracetam | 62613-82-5 | Hydroxy-piracetam racetam | USD 145 – 165 / kg | 1 kg · 5 kg · 25 kg |
| Hydrafinil (fladrafinil, CRL-40,941) | 1689-64-1 | Modafinil analog, eugeroic class | USD 175 – 195 / kg | 1 g · 10 g · 100 g · 1 kg |
| Pramiracetam | 68497-62-1 | Lipophilic racetam,choline-uptake | USD 600 – 700 / kg | 1 g · 10 g · 100 g · 1 kg · 5 kg |
| Tropoflavin (4′-DMA-7,8-DHF) | 38183-03-8 | Flavone, TrkB partial agonist | USD 2,300 – 2,800 / kg | 1 g · 10 g · 100 g · 1 kg |
| NSI-189 free base | 1228666-02-7 | Isothiazole, hippocampal neurogenesis | USD 2,600 – 2,800 / kg | 100 mg · 1 g · 10 g · 100 g · 1 kg |
| NSI-189 phosphate (1:1) | 1228666-03-8 | Phosphate salt of NSI-189 | USD 2,800 – 3,200 / kg (vs free base) | 100 mg · 1 g · 10 g · 100 g · 1 kg |
4. Racetam Family — Piracetam, Aniracetam, Oxiracetam, Pramiracetam, Noopept
Five of the nine catalog SKUs are racetam-class compounds sharing the 2-oxo-1-pyrrolidine acetamide (piracetam) core. Off-pyrity in a quotation is the most common error here: a quote issued against piracetam is not valid for pramiracetam, and the structural difference is only an N,N-di-isopropyl substitution on the amide nitrogen — but the synthesis route, the chromatographic purification, and the impurity profile are entirely different.
4.1 Piracetam (CAS 7491-74-9)
Piracetam is the prototype racetam, originally marketed by UCB (Belgium) from 1964 as Nootropil. The molecule is a small, water-soluble, off-white crystalline powder with no chiral centre; the synthesis is a 2-route (γ-butyrolactone + glycine derivative → 2-oxo-1-pyrrolidine acetamide). In 2026, multiple API sites in China and India produce piracetam at multi-ton scale, all ≥ 99.5 % HPLC. T2 benchmarks cluster at USD 8 – 12 / kg at 1-ton lots and ~USD 18 – 22 / kg at 25 kg pack size; 1 g research pack runs USD 0.45 – 0.65 per gram.
4.2 Noopept / omberacetam (CAS 157115-85-0)
Noopept is the cyclic dipeptide N-(1-(phenylacetyl)-L-prolyl)glycine ethyl ester, structurally a racetam mimetic developed in Russia (IVEX / Lekko) in the 1990s. The synthesis is a 5-step peptide-coupling route with HPLC purification to ≥ 99 %; chiral purity is mandatory (L-proline). T2 benchmark in 2026 is USD 245 – 265 / kg at 1 kg pack; smaller packs carry the usual micro-scale premium. The product page lists the same SKU at 100 g pack with HPLC + LC-MS CoA.
4.3 Phenibut free acid (CAS 1078-21-3)
Phenibut is β-phenyl-γ-aminobutyric acid, a GABA-B agonist structurally derived from GABA by β-phenyl substitution; originally developed in Russia in the 1960s. The molecule is supplied as the free acid (CAS 1078-21-3) and as the hydrochloride (CAS 3060-40-2); the two salts are not interchangeable on a per-milligram basis — phenibut HCl is ~85.7 % free-acid equivalent. T2 benchmark in 2026 is USD 125 – 145 / kg at 25 kg pack for the free acid.
4.4 Aniracetam (CAS 72432-10-1) and Oxiracetam (CAS 62613-82-5)
Both are first-generation racetams with off-patent supply. Aniracetam (1-(4-methoxybenzoyl)-2-pyrrolidinone) carries an anisoyl group; oxiracetam (4-hydroxy-2-oxo-1-pyrrolidine acetamide) is the 4-hydroxy analogue of piracetam. T2 benchmarks cluster at USD 145 – 165 / kg for both, reflecting the similar synthesis complexity and the similar (modest) annual volume.
4.5 Pramiracetam (CAS 68497-62-1)
Pramiracetam is the N,N-di-isopropyl amide analogue of piracetam, developed by Parke-Davis in the late 1970s and licensed in some EU markets as Neupramir and Remen. It is structurally the most lipophilic of the prototype racetams and the most expensive of the four — T2 benchmark USD 600 – 700 / kg at 1 kg pack, driven by the di-isopropylamine coupling step and the lower annual volume. The full nootropic stack guide positions pramiracetam in the "specialty racetam" tier above the off-patent generics.
5. Eugeroic Wake-Promoter Cluster — Modafinil Analogs and Hydrafinil
The eugeroic cluster is the second price driver in this catalog. The five named molecules — modafinil, adrafinil, armodafinil, flmodafinil / CRL-40,940, and fladrafinil / hydrafinil / CRL-40,941 — share the benzhydryl-sulfinyl acetamide core. Hydrafinil (CRL-40,941) is the only member of this cluster carried as a catalog SKU at the 2026 wholesale tier; modafinil and armodafinil are Schedule IV controlled substances in the United States (DEA CFR 1308.14) and are not offered at the wholesale-research tier.
| Compound | CAS | Schedule (US) | T2 benchmark (USD / kg, 2026) | Catalog status |
|---|---|---|---|---|
| Modafinil | 68693-11-8 | CIV (DEA) | Not offered at research tier | Schedule IV — controlled |
| Adrafinil | 63547-13-7 | Unscheduled (withdrawn EU 2011) | Quote-only | Limited catalogue |
| Armodafinil | 112111-43-0 | CIV (DEA) | Not offered at research tier | Schedule IV — controlled |
| Flmodafinil (CRL-40,940) | 90280-13-0 | Unscheduled (research) | Quote-only | Custom synthesis |
| Fladrafinil / Hydrafinil (CRL-40,941) | 1689-64-1 | Unscheduled (research) | USD 175 – 195 / kg | Catalog SKU — 9th of 9 |
Hydrafinil is the bis-fluoro analogue of adrafinil with an additional hydroxyl on the sulfoxide; the original synthesis description is in the Lafon CRL-40,94x series. The molecule is unscheduled in the United States, the EU, the UK, China, and Japan as of September 2026. T2 wholesale benchmark sits at USD 175 – 195 / kg at 1 kg pack; 1 g research pack runs USD 6 – 9 / gram. A side-by-side comparison of the two unscheduled analogs is in the CRL-40,940 vs CRL-40,941 sourcing page.
6. NSI-189 — Free Base vs Phosphate Salt
NSI-189 is the isothiazolo-pyridine derivative developed by Neuralstem (now part of the consolidated intellectual-property estate) for hippocampal neurogenesis. The molecule is supplied as either the free base (CAS 1228666-02-7) or the 1:1 phosphate salt (CAS 1228666-03-8); the two are not interchangeable on a per-milligram basis. The phosphate salt is approximately 73.4 % free-base equivalent, so a 100 mg "NSI-189 phosphate" vial contains ~73.4 mg of free-base active.
Wholesale T2 benchmarks in 2026:
The premium on the phosphate form over the free base reflects (a) the salt-formation step and (b) the higher dissolution stability requested by formulation groups; the premium is not a per-milligram-active equivalence. Per-milligram-of-free-base equivalent, the phosphate form is approximately USD 3,815 – 4,360 / kg of free base, a 47 – 56 % premium. See the sourcing-positioning context in the IDRA-21 / NSI-189 / PRL-8-53 / GTS-21 comparison page.
7. Tropoflavin (4′-DMA-7,8-DHF) and the Flavone-Derivative Tier
Tropoflavin (4′-dimethylamino-7,8-dihydroxyflavone, CAS 38183-03-8) is the dimethylamino analogue of 7,8-dihydroxyflavone (7,8-DHF, same CAS). It acts as a TrkB partial agonist at the BDNF binding site; the parent flavone is also carried in the catalog at a lower tier. The synthesis route is flavone-specific — typically a Baker-Venkataraman rearrangement followed by Algar-Flynn-Oyamada cyclisation and selective demethylation — and the CDMO supplier pool for flavones overlaps less with the racetam CDMO pool.
The tropoflavin synthesis is one of the longer routes in the catalog: 7 – 9 steps including a methoxymethyl (MOM) protection / deprotection on the catechol and a final dimethylation step on the 4′-amino group. The CDMO premium reflects (a) the lower annual volume compared with the off-patent racetams and (b) the tighter specification on the 7,8-dihydroxy catechol (which oxidises under ambient air). T2 purity specification is typically ≥ 99.0 % HPLC with a residual-solvent panel including methanol ≤ 3,000 ppm and dichloromethane ≤ 600 ppm (ICH Q3C). See the flavone chemistry context in the 7,8-dihydroxyflavone sourcing page.
8. Export & Regulatory Workflow (HS 2922 / 2933 / 2937 / 2939)
The export side of nootropic APIs is fragmented by chemistry class. The four HS subheadings below cover the nine catalog SKUs and the most-common sepal/analog extensions.
| HS subheading | US HTS equivalent | Covers | Catalogue members |
|---|---|---|---|
| 2922.19 / 2922.50 | 2922.19 / 2922.50 | Amino-alcohols, amino-phenols, amino-acids and their esters / ethers | Piracetam (racetam lactam), oxiracetam (hydroxy-piracetam), NSI-189 amino-isothiazole |
| 2933.39 / 2933.99 | 2933.39 / 2933.99 | Heterocyclic compounds with N, isothiazole / pyridine derivatives | NSI-189 free base, NSI-189 phosphate |
| 2933.59 / 2933.69 | 2933.59 / 2933.69 | Pyrimidine / pyridine derivatives including pyrrolidinones | Aniracetam, pramiracetam |
| 2937.50 | 2937.50.00.00 (general duty 0 %) | Prostaglandins, thromboxanes, leukotrienes — n/a here, listed for reference vs the peptide price list | (none of the 9 SKUs) |
| 2939.79 / 2939.80 | 2939.79 / 2939.80 | Vegetable alkaloids, natural / synthetic — n/a here | (none of the 9 SKUs) |
The standard Aframely-side document pack on any of the nine SKUs is: Commercial Invoice + Packing List + Certificate of Analysis (HPLC + 1H-NMR + LC-MS, residual solvents per ICH Q3C) + Safety Data Sheet (SDS, 16-section GHS) + Certificate of Origin (China / India / EU depending on API site) + Import permit copy from the destination country. No licence is required for the destination country for any of the nine SKUs in 2026; the schedule-IV molecules (modafinil, armodafinil) are not in the catalog.
8.1 Section 301 and the China → US tariff line
China-origin shipments of HS 2922.19 and 2933.39 may attract Section 301 additional duties on entry into the United States. The applicable list and rate depend on the most recent USTR Federal Register notice; the broker-of-record at the destination port is the authoritative source on the rate applicable to a given shipment. India-origin shipments (R&D-free piracetam, aniracetam, oxiracetam) typically do not attract Section 301 but may attract countervailing-duty / antidumping orders applicable to specific Indian API sites — confirm with the broker. EU-origin and US-toll-manufactured shipments clear Section 301 by default.
9. CDMO Supplier Landscape — Polpharma, Biophore, Suven, R&S, Hybio, Shandong Octagon
The nootropic-API supply chain is more fragmented than the peptide supply chain. No single CDMO covers all 9 SKUs at T2 / T3; a typical catalog broker consolidates across 3–4 CDMO relationships to fill the 9-SKU grid.
Polpharma (Poland)
European racetam manufacturer, multi-decade piracetam site, CEP available for piracetam and aniracetam. Strong on T3 commercial cGMP, weaker on specialty racetams.
Biophore (India)
Hyderabad-based racetam CDMO, USDMF + EUGMP for piracetam and oxiracetam, growing noopept portfolio. Mid-range T2 / T3 partner.
Suven Pharma (India)
CDMO with pramiracetam and oxiracetam capacity, USDMF + CEP for several racetams; also a peptide CDMO (cross-references the peptide price list).
Hybio (China, Shenzhen)
Synthetic peptide CDMO with an emerging nootropic portfolio, including hydrafinil and tropoflavin. T2 / T3 capability, EUGMP audited.
Shandong Octagon (China)
Specialty nootropic CDMO, the primary NSI-189 free-base site for the catalog at T2. Newer entrant, capacity scaling through 2026-2027.
R&S Pharma (China, Zhejiang)
Specialty racetam CDMO with Noopept and phenibut portfolios, T2/T3 capability, USDMF filed for Noopept in 2025.
9.1 Capacity-and-allocation reality
Two structural facts shape 2026 allocation:
- Tropoflavin and NSI-189 are 1-2 CDMO dependent. Each has 1-2 active API sites globally; a single CDMO maintenance event or a single regulatory hold removes a non-trivial share of catalog supply. T2 RFQs on these two should carry a longer quote-validity window (30 days instead of the usual 14) and a written allocation confirmation.
- Off-patent racetam capacity is abundant. Piracetam, aniracetam, oxiracetam, Noopept, and phenibut each have 4+ commercial API sites globally; price-for-action RFQs on these five clear within the standard 14-day quote-validity.
10. Selection Guidance by Application
A first-pass nootropic-API grid for a typical 2026 research / formulation group:
| Application profile | Recommended SKU | Pack-size sweet spot | Wholesale T2 (USD / kg) |
|---|---|---|---|
| Reference compound for screening library | Piracetam (CAS 7491-74-9) | 1 g · 10 g | USD 8 – 12 / kg |
| Cholinergic-uptake mechanism assay | Pramiracetam (CAS 68497-62-1) | 1 g · 10 g · 100 g | USD 600 – 700 / kg |
| AMPA-positive allosteric modulator assay | Aniracetam (CAS 72432-10-1) | 1 kg · 5 kg | USD 145 – 165 / kg |
| BDNF / TrkB partial-agonist assay | Tropoflavin (CAS 38183-03-8) | 1 g · 10 g · 100 g | USD 2,300 – 2,800 / kg |
| Hippocampal-neurogenesis assay | NSI-189 free base (CAS 1228666-02-7) | 100 mg · 1 g · 10 g | USD 2,600 – 2,800 / kg |
| Wake-promotion / eugeroic screening | Hydrafinil (CAS 1689-64-1) | 1 g · 10 g · 100 g · 1 kg | USD 175 – 195 / kg |
| Generic-drug formulation (racetam class) | Piracetam / aniracetam / oxiracetam | 5 kg · 25 kg | USD 8 – 165 / kg |
10.1 Cross-cluster context
Several nootropic APIs sit at the intersection with other catalogs:
- Fasoracetam (CAS 110958-19-5) — not in the 9-SKU catalog but covered in the nootropic-coluracetam sourcing page and the nootropic-fasoracetam-powder sourcing page. Sourcing is on a different quote-on-same-basis tier from the 9.
- Coluracetam (CAS 135463-81-9) — also covered in the coluracetam sourcing page; specialty tier above the 9-SKU grid.
- trans-ISRIB (CAS 1597403-47-8) — cognitive research reagent but mechanistically an integrated-stress-response inhibitor, not a racetam; covered in the trans-ISRIB sourcing page.
- Cerebrolysin, Semax, Selank — peptide-class; see the peptide price list for the synthetic-peptide price grid.
11. Frequently Asked Questions
What pack sizes are available for each nootropic API in this catalog?
Pack sizes 1 g · 1 g offers research-scale access, 100 g is a typical animal-PD dose scale, 1 kg is the wholesale T2 pack size, and 5 kg · 5 kg to 25 kg are commercial cGMP pack sizes. The 1 g and 10 g packs typically carry a 30 – 60 × per-gram premium over the 1 kg pack; the 25 kg pack typically carries a 15 – 25 % per-gram discount over the 1 kg pack. Full price schedule per pack size is issued on RFQ.
Are these prices quoted per free base or per salt form?
Piracetam, aniracetam, oxiracetam, pramiracetam, Noopept, tropoflavin, NSI-189 free base, and hydrafinil are all quoted as the free base or the neutral molecule. Phenibut is quoted as the free acid by default and as the hydrochloride on RFQ. NSI-189 phosphate is quoted as the 1:1 phosphate salt, with the free-base equivalent (~73.4 %) listed separately on the CoA. The two salt forms of any one molecule are not interchangeable on a per-milligram basis.
Which of these 9 SKUs are Schedule IV in the United States?
None of the 9 catalog SKUs are Schedule IV in the United States. Modafinil (CAS 68693-11-8) and armodafinil (CAS 112111-43-0) are Schedule IV under 21 CFR 1308.14 and are not offered at the wholesale-research catalog tier. Adrafinil, flmodafinil (CRL-40,940), and fladrafinil / hydrafinil (CRL-40,941) are unscheduled in the US as of September 2026; local country regulations still apply.
What purity and residual-solvent panel comes standard at T2?
T2 purity is ≥ 99.0 % HPLC for all 9 SKUs, with an additional chiral-purity test on Noopept and NSI-189 (the only two with a stereocentre). The standard residual-solvent panel follows ICH Q3C: methanol ≤ 3,000 ppm, ethanol ≤ 5,000 ppm, acetone ≤ 5,000 ppm, dichloromethane ≤ 600 ppm, ethyl acetate ≤ 5,000 ppm. T3 commercial cGMP adds the ICH Q3D elemental-impurity panel and the USP <61> / <62> microbial panel.
Is a quote issued for piracetam valid for aniracetam or oxiracetam?
A quote issued for piracetam (CAS 7491-74-9) is not valid for aniracetam (CAS 72432-10-1), oxiracetam (CAS 62613-82-5), pramiracetam (CAS 68497-62-1), or Noopept (CAS 157115-85-0). The five racetam-family SKUs differ in N-substituent, molecular weight, chiral purity, and CDMO supply chain; a quotation line item that does not carry the full CAS and the chiral / salt-form flag is to be re-issued with both.
Does the tropoflavin catalog include the parent 7,8-DHF or only the dimethylamino analogue?
The catalog carries tropoflavin (4′-DMA-7,8-DHF, CAS 38183-03-8) as the 9th SKU. The parent 7,8-dihydroxyflavone (7,8-DHF, same CAS 38183-03-8 — the two flavones share the same CAS number) is available on RFQ at a lower T2 tier, typically USD 1,800 – 2,200 / kg at 1 kg pack. The two molecules share a CAS by registration convention; the CoA and the HS classification should both carry the explicit flavone identity to avoid a quotation-line ambiguity.
Can NSI-189 phosphate be substituted for NSI-189 free base on a per-milligram basis?
No. NSI-189 phosphate (1:1 salt, CAS 1228666-03-8) is approximately 73.4 % free-base equivalent. A 100 mg sample of NSI-189 phosphate contains ~73.4 mg of free-base active. Per-milligram-of-free-base equivalent, the phosphate form is approximately 47 – 56 % more expensive than the free base. The two salt forms are not interchangeable on a per-milligram basis in either pharmacological or quotation contexts.
What HS subheading covers piracetam, and what is the China → US duty line?
Piracetam (CAS 7491-74-9) is classified under HS 2922.19 (amino-alcohols / amino-phenols / amino-acids and their derivatives) or HS 2933.79 (lactams) depending on the destination country's tariff schedule. China-origin shipments may attract Section 301 additional duties on entry into the United States; the applicable list and rate depend on the most recent USTR Federal Register notice. India-origin shipments may attract countervailing-duty / antidumping orders on specific Indian API sites. The broker-of-record at the destination port is the authoritative source on the rate applicable to a given shipment.
Is phenibut HCl interchangeable with phenibut free acid?
No. Phenibut free acid (CAS 1078-21-3) and phenibut hydrochloride (CAS 3060-40-2) differ in molecular weight (free acid 179.22, HCl salt 215.68) and in free-acid content (~83.1 % in the HCl salt). A 100 mg sample of phenibut HCl contains ~83.1 mg of free-acid active. Per-milligram-of-free-acid equivalent, the HCl salt is ~22 % more expensive than the free acid. The two are not interchangeable on a per-milligram basis in either pharmacological or quotation contexts.
What CDMO tier best fits a typical 2026 nootropic API quotation?
For off-patent racetams (piracetam, aniracetam, oxiracetam, Noopept, phenibut), the T2 tier is filled by 4+ commercial API sites globally; quotation is on the standard 14-day quote-validity window. For specialty racetams (pramiracetam) and flavone derivates (tropoflavin), the T2 tier is filled by 1-3 CDMO relationships; quotation carries a 30-day quote-validity window and a written allocation confirmation. For NSI-189 free base and phosphate, the T2 tier is dominated by a single CDMO relationship at Shandong Octagon; quotation is on the 30-day window.
How does the nootropic-API price list relate to the peptide price list?
The two price lists cover different chemistries with different CDMO pools. The peptide price list covers synthetic peptide CDMOs (Bachem, PolyPeptide, Lonza Peptisyntha, Hybio, CPC, Wuxi STA) and HS 3504 / 2937 export workflow. The nootropic price list covers racetam / flavone CDMOs (Polpharma, Biophore, Suven, R&S, Hybio, Shandong Octagon) and HS 2922 / 2933 / 2937 export workflow. Hybio is the only CDMO appearing in both lists, with separate quality systems for peptide vs nootropic API manufacture. For the cross-cluster context — fasoracetam, coluracetam, trans-ISRIB — see the dedicated sourcing pages listed in §10.1.
Can any of these 9 SKUs be supplied as a clinical-trial or pharmaceutical-grade material?
At T3 commercial cGMP, yes for piracetam, aniracetam, oxiracetam, pramiracetam, and Noopept. Each of these carries an active USDMF / EUCEP / ASMDF at one or more commercial CDMO sites. NSI-189 free base, NSI-189 phosphate, tropoflavin, and hydrafinil are research-use only at the T2 tier — no clinical-grade API is commercially available in 2026. T4 brand-innovator grade is not available for any of the 9 SKUs.
12. Request a Wholesale Quotation
Talk to the NutraBiotech wholesale desk
Standard RFQ reply within 2 working days · COA + 1H-NMR + LC-MS · pack sizes 1 g – 25 kg · RUO only · quote-validity 14 days for off-patent racetams, 30 days for specialty SKUs
Request a Quotation13. Conclusion
The 2026 nootropic-API price list is structurally a two-tier grid: a low-priced commodity tier (piracetam at USD 8 – 12 / kg, phenibut at USD 125 – 145 / kg, aniracetam / oxiracetam at USD 145 – 165 / kg, Noopept at USD 245 – 265 / kg, hydrafinil at USD 175 – 195 / kg) supplied by 4+ commercial API sites each, and a specialty tier (pramiracetam at USD 600 – 700 / kg, tropoflavin at USD 2,300 – 2,800 / kg, NSI-189 free base at USD 2,600 – 2,800 / kg, NSI-189 phosphate at USD 2,800 – 3,200 / kg) supplied by 1-3 specialty CDMOs each. The two tiers differ by an order of magnitude or more, and the difference is structural (synthesis-route complexity + annual volume), not a temporary market dislocation.
Three operational notes close the page:
- Quotation lines must carry CAS + chiral / salt-form flag. A quotation issued against one of these molecules is not valid for another — the two sets differ in molecular weight, chiral purity, residual-solvent panel, and regulatory dossier.
- The CDMO pool is fragmented. No single CDMO covers all 9 SKUs at T2 / T3; a typical catalog broker consolidates across 3-4 CDMO relationships. Allocation on tropoflavin and NSI-189 should be confirmed in writing.
- Schedule IV is on the CoA and the SDS Section 15, not on the HS code. None of the 9 SKUs are Schedule IV; modafinil and armodafinil are, and neither is in the catalog. A customs declaration with the correct HS code does not establish the schedule status of the API.